New combo therapy aims to extend life in tough pancreatic cancer

NCT ID NCT06361888

Recruiting now Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or standard chemo alone. The main goal is to see if the combo improves overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Nanjing Tianyinshan Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210000, China
Tianjin Cancer Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.